| USA |  |
chemeleon has created a novel platform technology for rapid, accurate and affordable diagnostics that are capable of detecting a broad range of analytes including drugs, proteins and viruses. this proprietary, in vitro diagnostic format provides a colorimetric readout in minutes, visual to the naked eye, without the need for any reagents, readers,instruments, equipment or training, providing truly decentralized testing that can enable clinicians to extend the point-of-care and laypeople to self-administer at the point-of-need. our diagnostics combine highly-selective molecular receptors with colorimetric nanomaterial reporters to provide immediate, actionable diagnosis to radically improve patient treatments and outcomes, while greatly reducing costs. under a grant from the nih, chemeleon developed this diagnostic to detect the protein biomarker, beta-2-transferrin, in order to enable healthcare practitioners to immediately identify and treat cerebrospinal fluid leaks in surgical, post-op and clinical settings which leads to a drastic decrease in morbidity (87% reduction in meningitis), length of patient stay (by up to a week) and healthcare costs (around $16,000 per patient). providing the same level of specificity and selectivity as lab-based tests, but in minutes (not days) with a hand-held, instrument-free diagnostic at a fraction of the cost means that this rapid, simple and inexpensive diagnostic can revolutionize healthcare from hospitals to resource-deprived regions. as per the who's criteria, our poc diagnostic is the definition of assured (affordable, sensitive, specific, user-friendly, rapid and robust, equipment-free and deliverable to end-users).
